Minerva Neurosciences will hold an in-person and virtual event on November 12, 2026, featuring experts discussing roluperidone, an investigational drug targeting the negative symptoms of schizophrenia. The event will cover new evidence supporting the drug's efficacy and safety, updates on the ongoing Phase 3 trial, and include a live Q&A session. Roluperidone aims to address symptoms like lack of motivation and social withdrawal, areas with no current FDA-approved treatments. This event highlights Minerva's progress in developing therapies for central nervous system disorders and the potential impact of roluperidone if approved.
Minerva Neurosciences event on roluperidone offers context for readers. For those tracking health stocks, 42 of 150 US health-sector stocks rose while 94 fell as of Oct 28, 2026, 17:41 WIB. Notable moves include NUWE at USD 4.75 with a -12.68% change and 100% sell orders, BNGO at USD 1.12 down 8.20%, and ACB at USD 4.44 up 6.99%.
Arcutis Biotherapeutics has appointed Dr. Rob Scott, a seasoned pharmaceutical executive with over 40 years of experience, to its Board of Directors. Dr. Scott's expertise in developing and securing approvals for innovative medicines, including derma...
Air Canada and CAE announced the opening of applications on November 1, 2026, for the 2027 Commandante-Judy-Cameron scholarships. These scholarships support up to eight Canadian women pursuing professional pilot or aircraft maintenance technician tra...
The Legacy Lab by Team One released its 2026 Legacy Makers 100 list, identifying brands consumers trust to have their best interests at heart and remain relevant long-term. St. Jude Children's Research Hospital topped the list for the second year. Th...
Circuit Mind has introduced AVE (Agentic Verification Engine), an AI-powered application that verifies printed circuit board (PCB) schematics against datasheets and internal design rules to catch errors early and avoid expensive respins. AVE compleme...
Grabar Law Office is investigating claims against officers and directors of Erasca, Planet Fitness, PROCEPT BioRobotics, and The Simply Good Foods Company for alleged breaches of fiduciary duties. The investigations focus on misleading statements and...
